GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » Receivables Turnover

Biogen (HAM:IDP) Receivables Turnover : 1.12 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Biogen Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Biogen's Revenue for the three months ended in Mar. 2024 was €2,107 Mil. Biogen's average Accounts Receivable for the three months ended in Mar. 2024 was €1,883 Mil. Hence, Biogen's Receivables Turnover for the three months ended in Mar. 2024 was 1.12.


Biogen Receivables Turnover Historical Data

The historical data trend for Biogen's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Receivables Turnover Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.87 5.34 5.33 5.12 4.58

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 1.18 1.18 1.10 1.12

Competitive Comparison of Biogen's Receivables Turnover

For the Drug Manufacturers - General subindustry, Biogen's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Receivables Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Biogen's Receivables Turnover falls into.



Biogen Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Biogen's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Receivables Turnover (A: Dec. 2023 )
=Revenue / Average Total Inventories
=Revenue (A: Dec. 2023 ) / ((Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count )
=9019.245 / ((2016.762 + 1925.7) / 2 )
=9019.245 / 1971.231
=4.58

Biogen's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

Receivables Turnover (Q: Mar. 2024 )
=Revenue / Average Total Inventories
=Revenue (Q: Mar. 2024 ) / ((Accounts Receivable (Q: Dec. 2023 ) + Accounts Receivable (Q: Mar. 2024 )) / count )
=2107.26 / ((1925.7 + 1839.724) / 2 )
=2107.26 / 1882.712
=1.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (HAM:IDP) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


Biogen Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Biogen's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (HAM:IDP) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (HAM:IDP) Headlines

No Headlines